 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
19 News |  |
- | AEOL 10150 / Aeolus
Journal: AEOL 10150 Alleviates Radiation-induced Innate Immune Responses in Non-human Primate Lung Tissue. (Pubmed Central) - Mar 12, 2022
Cytokine/chemokine-induced excessive innate immune response after thoracic irradiation plays an important role in RILI. To our knowledge, this is the first study to highlight the role of cytokine/chemokine-induced innate immune responses in radiation-induced pulmonary toxicity in a NHP model.
- | BMX-010 / BioMimetix
Journal: Thermal Stability Kinetics and Shelf Life Estimation of the Redox-Active Therapeutic and Mimic of Superoxide Dismutase Enzyme, Mn(III) meso-Tetrakis(N-ethylpyridinium-2-yl)porphyrin Chloride (MnTE-2-PyPCl, BMX-010). (Pubmed Central) - Mar 1, 2022
According to the R1 modelling of the isothermal decomposition data, the estimated shelf life value for 10% decomposition (t ) of MnTE-2-PyPCl at 25°C was approximately 17 years, which is consistent with the high solid-state stability of the compound. These results represent the first study on the solid-state decomposition kinetics of Mn(III) 2-N-alkylpyridylporphyrins, contributing to the development of this class of redox-active therapeutics and SOD mimics and providing supporting data to protocols on purification, handling, storage, formulation, expiration date, and general use of these compounds.
- | BMX-001 / BioMimetix, AEOL 10113 / Aeolus, BMX-010 / BioMimetix
Journal: Ortho Isomeric Mn(III) N-Alkyl- and Alkoxyalkylpyridylporphyrins-Enhancers of Hyaluronan Degradation Induced by Ascorbate and Cupric Ions. (Pubmed Central) - Sep 10, 2021
The impact of different Mn(III)-porphyrins on the HA decay was further clarified by electron paramagnetic resonance spectrometry. The ability to catalyze the degradation of HA in a biological milieu, in the presence of cupric ions and ascorbate under the conditions of high tumor oxidative stress provides further insight into the anticancer potential of redox-active ortho isomeric Mn(III) porphyrins.
- | AEOL-11203 / Aeolus, AEOL 10150 / Aeolus, AEOL 10113 / Aeolus
Journal: Reduction of peroxynitrite by some manganoporphyrins of AEOL series: DFT approach with dispersion correction and NBO analysis. (Pubmed Central) - Sep 3, 2021
In AEOL compounds and their association complexes with ONOO, Mn atom prefered the high spin state (S = 2) to the intermediate spin state (S = 1). Natural bond orbital analysis showed that electron transfer from the most negative oxygen atom in ONOO to Mn atom in MnP has the biggest interaction energy among all kinds of donor-acceptor interactions between ONOO and MnP.
- || BMX-001 / BioMimetix, AEOL 10113 / Aeolus, BMX-010 / BioMimetix
Review, Journal: HO-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways. (Pubmed Central) - May 20, 2021
The lead Mn porphyrins, namely, MnTE-2-PyP (BMX-010, AEOL10113), MnTnBuOE-2-PyP (BMX-001), and MnTnHex-2-PyP, were tested in numerous injuries of normal tissue and cellular and animal cancer models. The wealth of the data led to the progression of MnTnBuOE-2-PyP into four Phase II clinical trials on glioma, head and neck cancer, anal cancer, and multiple brain metastases, while MnTE-2-PyP is in Phase II clinical trial on atopic dermatitis and itch.
- | AEOL 11207 / Aeolus, AEOL-1114B / Aeolus
Preclinical, Journal: Optimization of lipophilic metalloporphyrins modifies disease outcomes in a rat model of parkinsonism. (Pubmed Central) - May 15, 2021
Both compounds significantly attenuated dopamine depletion, cytokine production, microglia activation, dopaminergic neuronal loss, oxidative/nitrative stress indices and behavioral abnormality in a Parkinson's disease rat model. The results suggest that both metalloporphyrins possess disease-modifying properties which may be useful in treating Parkinson's disease.
- | BMX-001 / BioMimetix, AEOL 10113 / Aeolus, BMX-010 / BioMimetix
Preclinical, Journal: Mn porphyrins as a novel treatment targeting sickle cell NOXs to reverse and prevent acute vaso-occlusion in vivo. (Pubmed Central) - May 11, 2021
Our data suggest that Mn porphyrins, likely by repressing NOX-mediated adhesive function of SSRBCs and activated leukocytes, could represent a novel, safe therapeutic intervention to treat or prevent the establishment of acute pain crises. These NOX-targeted antioxidants merit further assessment in SCD clinical trials.
- | AEOL 10150 / Aeolus
Journal: Identifying Circulating and Lung Tissue Cytokines Associated with Thoracic Irradiation and AEOL 10150 Treatment in a Nonhuman Primate Model. (Pubmed Central) - Dec 16, 2020
Statistical analysis indicated that circulating cytokines could be discriminatory predictors of AEOL 10150 treatment. Taken together, our data suggested that the cytokine profiles were significantly changed after WTLI as well as mitigator treatment, and that the plasma cytokine profiles could potentially be used to distinguish vehicle or mitigator treatment after WTLI in a NHP model.
- | BMX-010 / BioMimetix
Journal: Redox-Active Drug, MnTE-2-PyP, Prevents and Treats Cardiac Arrhythmias Preserving Heart Contractile Function. (Pubmed Central) - Nov 18, 2020
MnTE-2-PyP prevents and treats cardiac arrhythmias in rats. In contrast to most antiarrhythmic drugs, MnTE-2-PyP preserves cardiac contractile function, arising, thus, as a prospective therapeutic for improvement of cardiac arrhythmia treatment.
- || avasopasem manganese (GC4419) / Galera Therap
Clinical, Journal: May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients? (Pubmed Central) - Oct 21, 2020
P2
announced the dosing of the first patient in a randomized, double-blind pilot phase II clinical trial with GC4419 for COVID-19. The study was first posted on ClinicalTrials.gov (Identifier: NCT04555096) 18 September 2020.
- || dexamethasone / generics
Review, Journal: Emergency management of chlorine gas exposure - a systematic review. (Pubmed Central) - Nov 27, 2019
However, these recommendations are based on low-level quality data. A systematic list of outcomes to monitor and improve may help to design optimal therapeutic protocols to manage chlorine-exposed patients.
- | BMX-001 / BioMimetix, AEOL 10113 / Aeolus
Journal: Mn porphyrin-based redox-active drugs - Differential effects as cancer therapeutics and protectors of normal tissue against oxidative injury. (Pubmed Central) - Oct 4, 2019
A systematic list of outcomes to monitor and improve may help to design optimal therapeutic protocols to manage chlorine-exposed patients. Studies that simultaneously explore differential effects in same animal are lacking, while they are essential for understanding of extremely intricate interactions of metal-based drugs with complex cellular networks of normal and cancer cells/tissues.
- | AEOL 10113 / Aeolus
Clinical, Journal: MnSOD is implicated in accelerated wound healing upon Negative Pressure Wound Therapy (NPWT): A case in point for MnSOD mimetics as adjuvants for wound management. (Pubmed Central) - Mar 23, 2019
...As a proof of concept and to outline the important role of SOD activity in wound healing, we replaced NPWT by the topical application of a MnSOD mimetic, Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP, MnE, BMX-010, AEOl10113) in the rodent model...Taken together, these results show for the first time a link between NPWT and regulation of antioxidant mechanism through the maintenance of MnSOD activity. Additionally this discovery outlined the potential role of MnSOD mimetics as topical agents enhancing wound healing.